Cipla, a leading pharmaceutical company, has partnered with ImmunoACT, a biotech firm, to launch CAR-T cell therapy for the treatment of blood cancers in Africa. This collaboration aims to make this innovative and potentially life-saving treatment more accessible to patients in the region.<\/p>\n
CAR-T cell therapy is a form of immunotherapy that involves extracting a patient’s T cells, genetically modifying them to recognize and attack cancer cells, and then reinfusing them back into the body. This treatment has shown remarkable success in treating certain types of blood cancers, including leukemia and lymphoma.<\/p>\n
The partnership between Cipla and ImmunoACT will enable the development and commercialization of CAR-T cell therapy in Africa, where access to such treatments is currently limited. Cipla will leverage its extensive distribution network and manufacturing capabilities to support the launch of the therapy, while ImmunoACT will provide its expertise in CAR-T cell technology and clinical development.<\/p>\n
The launch of CAR-T cell therapy in Africa is a significant milestone, as it has the potential to transform the treatment landscape for blood cancers in the region. Currently, many patients in Africa lack access to effective treatments for these diseases, resulting in poor outcomes and high mortality rates. The introduction of CAR-T cell therapy is expected to improve treatment options and outcomes for these patients.<\/p>\n
The partnership also highlights the growing importance of collaboration between pharmaceutical companies, biotech firms, and healthcare providers in addressing the complex challenges of cancer treatment in Africa. By working together, these stakeholders can pool their resources, expertise, and knowledge to develop and deliver innovative treatments that can make a meaningful difference in the lives of patients.<\/p>\n
In addition to improving treatment options, the launch of CAR-T cell therapy in Africa is also expected to drive awareness and education about blood cancers and the importance of early diagnosis and treatment. This, in turn, can help to reduce stigma and promote a better understanding of these diseases, ultimately leading to improved health outcomes for patients and their families.<\/p>\n
Overall, the partnership between Cipla and ImmunoACT to launch CAR-T cell therapy in Africa represents a significant step forward in the fight against blood cancers in the region. By making this innovative treatment more accessible, the partners aim to improve treatment options, outcomes, and quality of life for patients, while also driving awareness and education about these diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"
Cipla, a leading pharmaceutical company, has partnered with ImmunoACT, a biotech firm, to launch CAR-T cell therapy for the treatment of blood cancers in Africa. This collaboration aims to make this innovative and potentially life-saving treatment more accessible to patients in the region. CAR-T cell therapy is a form of immunotherapy that involves extracting a […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17,2],"tags":[],"class_list":["post-89830","post","type-post","status-publish","format-standard","hentry","category-cipla","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89806,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/us-sales-of-revlimid-decline-offset-by-strong-domestic-market-growth\/","url_meta":{"origin":89830,"position":0},"title":"US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue\u2026","rel":"","context":"In "Cipla"","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89862,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/26\/several-major-indian-pharmaceutical-companies-including-sun-pharma-cipla-zydus-and-graviti-have-issued-recalls-for-certain-medications-in-the-united-states-market\/","url_meta":{"origin":89830,"position":1},"title":"Several major Indian pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti, have issued recalls for certain medications in the United States market.","author":"Team Small News","date":"January 26, 2026","format":false,"excerpt":"Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems with impurities, quality control, and production processes. Sun Pharma is recalling over 24,000\u2026","rel":"","context":"In "Cipla"","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89805,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/a-14-year-old-patient-suffering-from-sickle-cell-disease-undergoes-hip-replacement-surgery-at-apollo-hospital\/","url_meta":{"origin":89830,"position":2},"title":"A 14-year-old patient suffering from sickle cell disease undergoes hip replacement surgery at Apollo Hospital.","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"A 14-year-old girl from Nigeria, Grace Natasha Mwanasa, has undergone a successful total hip replacement surgery at Indraprastha Apollo Hospital in New Delhi. The surgery, led by renowned orthopaedic surgeon Dr. Yash Gulati, is one of the youngest cases of total hip arthroplasty in a patient with sickle cell disease.\u2026","rel":"","context":"In "Apollo Hospital"","block_context":{"text":"Apollo Hospital","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/apollo-hospital\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89682,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/18\/glenmark-secures-1-billion-deal-for-multi-regional-rights-to-hansoh-pharmas-cancer-treatment-medication\/","url_meta":{"origin":89830,"position":3},"title":"Glenmark secures $1 billion deal for multi-regional rights to Hansoh Pharma’s cancer treatment medication.","author":"Team Small News","date":"December 18, 2025","format":false,"excerpt":"Glenmark Specialty S.A., a subsidiary of India-based Glenmark Pharmaceuticals, has entered into a licensing agreement with China's Jiangsu Hansoh Pharmaceutical Group Co. for the oncology drug Aumolertinib. The agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib in several high-potential markets, including the Middle East, Africa, Southeast and South\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89869,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/27\/zydus-lifesciences-introduces-indias-first-biosimilar-version-of-nivolumab-a-global-breakthrough\/","url_meta":{"origin":89830,"position":4},"title":"Zydus Lifesciences introduces India’s first biosimilar version of Nivolumab, a global breakthrough.","author":"Team Small News","date":"January 27, 2026","format":false,"excerpt":"Zydus Lifesciences, a leading life sciences company, has launched the world's first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in the field of Immuno-Oncology. Tishtha will be available in two dosage strengths, 100\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89830,"position":5},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89830"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89830\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}